Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's Return-on-Tangible-Equity is ranked better than 77.75% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs CAI:PHAR: 19.14
Egyptian International Pharmaceutical Investments (CAI:PHAR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Related Terms
Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity Chart
Egyptian International Pharmaceutical Investments Annual Data
CAI:PHAR vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments Return-on-Tangible-Equity vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 19.25% mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Return-on-Tangible-Equity of 19.25% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 17% below median its historical median of 23.09. Over the past decade, Egyptian International Pharmaceutical Investments' Return-on-Tangible-Equity has ranged from 16.80 to 29.62. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #200 out of 899 companies in the Drug Manufacturers industry, placing it in the top 22.2%.
Is Egyptian International Pharmaceutical Investments' Return-on-Tangible-Equity too high?
Egyptian International Pharmaceutical Investments' current Return-on-Tangible-Equity of 19.25% is 17% below median its 10-year median of 23.09. Over the past 10 years, this metric has ranged from a low of 16.80 to a high of 29.62. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.95. Egyptian International Pharmaceutical Investments' value of 19.25% is 142.1% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #200 out of 899 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #200 out of 899 companies for Return-on-Tangible-Equity. This places Egyptian International Pharmaceutical Investments in the top 22% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.95. Egyptian International Pharmaceutical Investments' value of 19.25% is 142.1% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own Return-on-Tangible-Equity has ranged from 16.80 to 29.62 over the past decade. While the company's 10-year median is 23.09 vs. the industry median of 7.95, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.95, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current Return-on-Tangible-Equity of 19.25% is 142.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current Return-on-Tangible-Equity is 19.25%, which is 17% below median its own 10-year median of 23.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.86, compared to a current price of E£90.88 — trading 51.8% above its estimated fair value. The current Return-on-Tangible-Equity is 19.25%, which is 17% below median its 10-year median of 23.09 and 142.1% above the Drug Manufacturers industry median of 7.95. Egyptian International Pharmaceutical Investments' overall GF Score™ is 71/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Return-on-Tangible-Equity is 19.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£90.88 is trading 51.8% above its estimated GF Value™ of E£59.86.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Return-on-Tangible-Equity: 19.25% (17% below median its 10-year median of 23.09)
GF Value™: E£59.86 vs. price of E£90.88 (51.8% above fair value)
Industry Position: 142.1% above the Drug Manufacturers median (#200 of 899)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
71GF Score
Get the complete analysis for CAI:PHAR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
